Kite Pharma Company Profile (NASDAQ:KITE)

Analyst Ratings

Consensus Ratings for Kite Pharma (NASDAQ:KITE) (?)
Ratings Breakdown: 1 Hold Rating(s), 14 Buy Rating(s)
Consensus Rating:Buy (Score: 2.93)
Consensus Price Target: $76.62 (50.97% upside)

Analysts' Ratings History for Kite Pharma (NASDAQ:KITE)
Show:
DateFirmActionRatingPrice TargetActions
7/22/2016MizuhoReiterated RatingBuy$80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Canaccord GenuityReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Stifel NicolausBoost Price TargetHold -> Buy$63.00 -> $74.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/9/2016Jefferies GroupReiterated RatingBuy$72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/10/2016FBR & CoReiterated RatingOutperform$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Barclays PLCInitiated CoverageEqual Weight$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Raymond James Financial Inc.Initiated CoverageOutperform$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2016SunTrust Banks Inc.Reiterated RatingBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$111.00 -> $92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2015Standpoint ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015GuggenheimReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Credit Suisse Group AGReiterated RatingOutperform$79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Kite Pharma (NASDAQ:KITE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($1.08)($0.60)$4.61 million$5.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.71)($0.54)$4.54 million$4.89 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.64)($0.38)$4.06 million$5.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.40)($0.48)$2.51 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115$0.12($0.36)$19.70 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.20)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kite Pharma (NASDAQ:KITE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.37)($0.93)($1.09)
Q2 20163($1.30)($1.15)($1.24)
Q3 20163($1.71)($1.65)($1.69)
Q4 20163($2.19)($2.05)($2.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kite Pharma (NASDAQ:KITE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kite Pharma (NASDAQ:KITE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/1/2016Jeffrey WiezorekSVPSell1,500$50.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2016Cynthia M ButittaCOOSell20,000$50.71$1,014,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Roy DoumaniDirectorSell10,000$57.91$579,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Jeffrey WiezorekSVPSell3,000$50.65$151,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Cynthia M ButittaCFOSell10,000$50.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Jeffrey WiezorekSVPSell9,000$44.88$403,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Margo R RobertsInsiderSell8,506$45.23$384,726.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Rizwana F SprouleVPSell8,500$45.27$384,795.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Cynthia M. ButittaCFOSell10,000$50.03$500,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Margo R. RobertsinsiderSell9,632$45.06$434,017.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Rizwana F. SprouleVPSell9,567$45.08$431,280.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Margo R. RobertsinsiderSell18,750$64.16$1,203,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2016Cynthia M. ButittaCFOSell1,900$50.13$95,247.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Marc BetterVPSell9,000$47.34$426,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016Cynthia M. ButittaCFOSell8,100$51.62$418,122.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Rizwana F. SprouleVPSell9,567$55.49$530,872.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Jeffrey WiezorekSVPSell9,000$55.26$497,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Margo R. RobertsinsiderSell6,145$55.22$339,326.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Marc BetterVPSell9,000$61.53$553,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Cynthia M. ButittaCFOSell10,000$61.56$615,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Cynthia M. ButittaCFOSell15,000$86.45$1,296,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Jeffrey WiezorekSVPSell9,000$78.08$702,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Margo R. RobertsinsiderSell6,145$78.16$480,293.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Rizwana F. SprouleVPSell9,567$78.13$747,469.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015David D. ChangEVPSell7,700$71.08$547,316.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Marc BetterVPSell9,000$71.07$639,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Cynthia M. ButittaCFOSell10,000$69.91$699,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Jeffrey WiezorekSVPSell9,000$62.59$563,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Margo R. RobertsinsiderSell6,145$62.57$384,492.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Rizwana F. SprouleVPSell9,567$62.58$598,702.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015David D. ChangEVPSell7,700$55.11$424,347.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Marc BetterVPSell9,000$54.81$493,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Cynthia M. ButittaCFOSell10,000$55.87$558,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Margo R. RobertsinsiderSell6,145$64.33$395,307.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Rizwana F. SprouleVPSell9,567$64.36$615,732.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015David D. ChangEVPSell7,700$55.00$423,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Marc BetterVPSell9,000$51.81$466,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015Cynthia M. ButittaCFOSell10,000$53.62$536,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Jeffrey WiezorekVPSell9,000$60.87$547,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Margo R RobertsInsiderSell6,145$60.90$374,230.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015David D ChangEVPSell7,700$61.92$476,784.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Marc BetterVPSell9,000$61.90$557,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Cynthia M ButittaCFOSell10,000$59.65$596,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Jeffrey WiezorekVPBuy4,000$17.00$68,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David D ChangEVPSell7,700$56.98$438,746.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Margo R RobertsInsiderSell8,625$56.99$491,538.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Rizwana F SprouleVPSell9,567$56.98$545,127.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Ran NussbaumDirectorSell305,434$55.35$16,905,771.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Marc BetterVPSell9,000$54.60$491,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Ran NussbaumDirectorSell80,760$55.34$4,469,258.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Cynthia M ButittaCFOSell10,000$59.76$597,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015Ran NussbaumDirectorSell193,730$60.45$11,710,978.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kite Pharma (NASDAQ:KITE)
DateHeadline
07/24/16 12:54 PM[$$] Bloodlines: Rivals look to create 'off-the-shelf' treatment - [at Financial Times] - Most of the companies pursuing Car-T therapies are developing products that modify cells taken from the patient's own blood. The process is complex, costly and logistically challenging, prompting sceptics ...
07/23/16 08:50 AMKite Pharma, Inc. (NASDAQ:KITE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 07:08 AMKite Pharma, Inc. breached its 50 day moving average in a Bullish Manner : KITE-US : July 22, 2016 -
07/21/16 05:00 PMKite Pharma Incorporated (NASDAQ:KITE) Short Interest Increased By 3.17% - Consumer Eagle
07/21/16 05:00 PMKite Pharma (NASDAQ:KITE) soared 5.17%: Marvell Technology Group Ltd. (NASDAQ:MRVL), The Walt Disney ... - KC Register
07/21/16 05:00 PMEquity Roundup: Stock Performance Focus on Kite Pharma, Inc. (NASDAQ:KITE) - Press Telegraph
07/20/16 02:57 PMStock Focus: Following Analyst Expectations on Shares of Kite Pharma, Inc. (NASDAQ:KITE) - TGP
07/20/16 02:57 PMOXIS International, Inc. (OTCMKTS:OXIS) & Kite Pharma Inc (NASDAQ:KITE) Provide Safe Haven for Investors for ... - Journal Transcript
07/20/16 02:57 PMEarnings Focus and Crowd Sourced Sentiment Review for Kite Pharma, Inc. (NASDAQ:KITE) - TGP
07/20/16 02:57 PMSolid Performer in Focus: Kite Pharma, Inc. (NASDAQ:KITE) - Engelwood Daily
07/18/16 02:55 PMKite Pharma, Inc. – Value Analysis (NASDAQ:KITE) : July 18, 2016 -
07/18/16 10:06 AMHow Many Kite Pharma Inc (NASDAQ:KITE)'s Analysts Are Bullish? - Consumer Eagle
07/17/16 09:11 AMKite Pharma, Inc. (NASDAQ:KITE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/16/16 08:13 AMKite Pharma Inc Realized Volatility Hits a Dropping Level - CML News
07/15/16 03:53 PMStifel Nicolaus issued a report on (NASDAQ:KITE) Kite Pharma, stepping up its target price to $74 today
07/15/16 08:51 AMKite Pharma Inc. (KITE) is Trading Higher on Unusual Volume for July 13 - Equities.com
07/14/16 03:30 PMJuno Therapeutics Falls After Correcting Number Of Trial Deaths -
07/14/16 08:27 AMBarclays Initiates Coverage on Kite Pharma Inc to Equal-weight - TheFounders Daily
07/14/16 08:27 AMHot Biotech Stocks Recap: Kite Pharma, Inc. (NASDAQ:KITE), Rock Creek Pharmaceuticals, Inc. (OTC:RCPI) - The Voice Registrar
07/14/16 08:27 AMKite Pharma Inc Stock Momentum at Critical Inflection Point - CML News
07/13/16 05:15 PMJUNO is flying, MIK is off and NTDOY is plateauing after big gains
07/13/16 05:15 PMKite Pharma (KITE) Jumps as Drug Trials Resume
07/13/16 05:15 PMJuno Therapeutics, Kite Pharma, & Petrobras Among the Morning’s Trending Stocks
07/12/16 05:06 PMBothell-based BioLife Solutions signs 10 year supply agreement with Kite Pharma
07/12/16 09:13 AMBioLife Solutions inks 10-year supply pact with Kite Pharma for CryoStor use in CAR T cell therapies
07/12/16 09:13 AMBioLife Solutions Inc. (BLFS) Surged After Supply Agreement
07/12/16 09:12 AMCryogenic Freezing Company BioLife (BLFS) Inks 10-Year Supply Deal
07/11/16 04:53 PMKite Pharma (KITE) Down on BioLife Deal
07/11/16 04:53 PMBioLife Options Executes 10 Yr Provide Agreement with Kite Pharma for CryoStor® Use in CAR T Cell Therapies. South Carolina SC
07/11/16 04:53 PMBioLife Solutions Executes 10 Year Supply Agreement With Kite Pharma
07/11/16 04:53 PMBuzz Stocks: Tesla Motors Inc, Wal-Mart Stores, Inc., and Kite Pharma Inc
07/11/16 09:33 AMStock to Focus on: Kite Pharma, Inc. (NASDAQ:KITE) - News Oracle
07/11/16 09:33 AMStock Rating Watch and Earnings Insight for Kite Pharma, Inc. (NASDAQ:KITE) - Press Telegraph
07/11/16 09:33 AMHC Stocks to watch for: Kite Pharma Inc (NASDAQ:KITE), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) - share market updates (press release)
07/11/16 09:33 AMWhiting Petroleum (NYSE:WLL) & Kite Pharma Inc (NASDAQ:KITE) Are Stocks to Keep Your Eyes on - Money News (press release)
07/11/16 09:02 AMKite Pharma, Inc. breached its 50 day moving average in a Bearish Manner : KITE-US : July 11, 2016 -
07/11/16 07:53 AMBioLife's stock nearly doubles after supply pact announced -
07/09/16 08:13 AMJuno Trial Put on Hold After 3 Patient Deaths; Stock Plunges (3)
07/08/16 04:58 PMUnusual Volume on Shares of: Kite Pharma, Inc. (NASDAQ:KITE) - Engelwood Daily
07/08/16 04:58 PMBRIEF-Kite Pharma completes enrollment of all patients with DLBCL in Phase 2 study of KTE-C19 - Reuters
07/08/16 04:58 PMKite Pharma, Inc. (NASDAQ:KITE) Earns Consensus Buy Rating - Review Fortune
07/08/16 04:58 PMMovers And Shakers In Biotech: Kite Pharma Inc (NASDAQ:KITE) And Eleven Biotherapeutics Inc (NASDAQ:EBIO) - Market Exclusive
07/08/16 04:58 PMFBR Weighs In on Two Falling Biotechs: Juno Therapeutics Inc (JUNO), Kite Pharma Inc (KITE) - Smarter Analyst
07/08/16 02:11 PMJuno Therapeutics (JUNO) Stock Will Rise Again, RBC's Yee Tells CNBC -
07/08/16 07:45 AMKite Pharma, Inc. (NASDAQ:KITE): Tracking Consensus Projections and Analyst Ratings - Telanagana Press
07/08/16 07:45 AMCompany Stock Focus for Kite Pharma, Inc. (NASDAQ:KITE): Which Way Will Shares Head? - Press Telegraph
07/08/16 07:45 AMKite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center ... - Yahoo Finance
07/08/16 07:45 AMKite Pharma Inc. Realized Volatility Hits a Dropping Level - CML News
07/08/16 05:50 AMFeuerstein: Assessing the Impact of Juno's Cancer CAR-T Stumble on Biotech Stocks -
07/08/16 02:01 AM3:01 am Kite Pharma completes the enrollment of Phase 2 Study of KTE-C19; interim efficacy results and BLA filing expected in 2016 -

Social

About Kite Pharma

Kite Pharma logoKite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KITE
  • CUSIP:
Key Metrics:
  • Previous Close: $50.75
  • 50 Day Moving Average: $50.92
  • 200 Day Moving Average: $48.77
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $2.50B
  • Beta: 2.46
  • Current Year EPS Consensus Estimate: $-5.83 EPS
  • Next Year EPS Consensus Estimate: $-6.37 EPS
Additional Links:
Kite Pharma (NASDAQ:KITE) Chart for Monday, July, 25, 2016